Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance.
Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance.
复制标题
鲑鱼降钙素治疗佩吉特骨病。
DOI：
10.1002/art.1780231012
复制
发表时间：
1980
影响因子：
--
通讯作者：
Minkin,C
中科院分区：
文献类型：
--
作者：
Singer,FR;Fredericks,RS;Minkin,C
在用鲑鱼降钙素长期治疗佩吉特骨病的最初几个月期间，循环碱性磷酸酶活性和尿羟脯氨酸排泄通常降低约50%。在85例患者中，22例患者的这些参数恢复到治疗前水平，尽管持续治疗。19例对鲑鱼降钙素耐药的患者具有高滴度的鲑鱼降钙素抗体。人降钙素在抑制这些患者的疾病活动方面是有效的。无抗体患者降钙素抵抗的发病机制尚不清楚。
During the initial months of long‐term treatment of Paget's disease of bone with salmon calcitonin, circulating alkaline phosphatase activity and urinary hydroxyproproline excretion usually decrease by about 50%. In 22 of 85 patients these parameters returned to pretreatment levels despite continuous therapy. Nineteen patients who were resistant to salmon calcitonin had salmon calcitonin antibodies in high titer. Human calcitonin has been effective in suppressing disease activity in these patients. The pathogenesis of calcitonin resistance in patients without antibodies is unknown.